Kezar Life Sciences, Inc. is a clinical-stage biotech company based in South San Francisco that is focused on discovering and developing small molecule therapeutics to treat immune-mediated diseases and cancer in the United States. The company's lead product candidate, zetomipzomib (KZR-616), is a selective immunoproteasome inhibitor that is currently in Phase 2b clinical trials to treat conditions like lupus nephritis, dermatomyositis, and polymyositis. Additionally, the product candidate is undergoing Phase 1b clinical trials for systemic lupus erythematosus, and has already completed Phase 2a clinical trials for lupus nephritis. Kezar's other preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor to treat tumors that are resistant to traditional chemotherapeutics, and KZR-TBD to treat oncology and immunology. The company, which was founded in 2015, continues its mission to tackle unmet medical needs with its innovative therapies.
Kezar Life Sciences, Inc.'s ticker is KZR
The company's shares trade on the ASX stock exchange
They are based in West Perth, Australia
There are 1-10 employees working at Kezar Life Sciences, Inc.
It is https://kezarlifesciences.com/
Kezar Life Sciences, Inc. is in the Basic Materials sector
Kezar Life Sciences, Inc. is in the Gold industry
The following five companies are Kezar Life Sciences, Inc.'s industry peers: